Volume 12, Number 4 (Nov/Dec 2021)

CDK4/6 Inhibitors: Paving the Way for HR-Positive, HER2-Negative Early Breast Cancer

This supplement to JADPRO reviews the latest emerging evidence for CDK4/6 inhibitors in the adjuvant setting for early breast cancer. Interprofessional perspectives and recommendations for improving adherence and side effect management are featured.

Faculty

Kristi K. Orbaugh, MSN, NP, AOCN®
Community Hospital Oncology Physicians
Zionsville, Indiana

Val R. Adams, PharmD, FCCP, BCOP, FHOPA
Markey Cancer Center at the University of Kentucky
Lexington, Kentucky

Theresa W. Gillespie, PhD, MA, RN, FAAN
Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com